Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Parkinson's Disease: Treatment

Parkinson's Disease: Treatment

Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...

Parkinson's Disease: Overview

Parkinson's Disease: Overview

Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is to...

Parkinson Disease l: Introduction

Parkinson Disease l: Introduction

Parkinson’s disease is a chronic, progressive neurodegenerative disorder that primarily affects movement. It is characterized by motor symptoms such as resting tremors, muscle rigidity, bradykinesia (slowness of movement), and postural instability. Patients may notice hand tremors at rest, stiffness during movement, or a shuffling gait. In addition to motor features, non-motor symptoms include sleep disturbances, mood and behavioral changes, constipation, and cognitive impairment, all of which...

Parkinson Disease ll: Pathophysiology

Parkinson Disease ll: Pathophysiology

Parkinson disease (PD) is a progressive neurodegenerative disorder primarily affecting movement, with additional non-motor features. Its pathophysiology involves complex interactions among genetic susceptibility, environmental exposures, and cellular dysfunction, including dopaminergic neuron loss, protein aggregation, and mitochondrial impairment.Selective NeurodegenerationA key feature is the degeneration of dopaminergic neurons in the substantia nigra pars compacta, leading to reduced...

Neural Regulation

Neural Regulation

Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Walking Recovery After Hip Fracture in Patients with Exceptional Longevity: Predictors and Association with Short- and Long-Term Survival.

Journal of clinical medicine·2026

Same author

Motor fluctuations in Parkinson's disease leave a distinct immune fingerprint in blood.

Parkinsonism & related disorders·2026

Same author

Expanding the clinical-radiological phenotype of SCA34 and its role in the differential diagnosis of the hot cross bun sign.

Journal of neurology·2025

Same author

Correspondence to: Use of levodopa-carbidopa intestinal gel to treat patients with multiple system atrophy.

Parkinsonism & related disorders·2025

Same author

Association of Epicardial Adipose Tissue with Novel Inflammation and Heart Failure Biomarkers in Type 2 Diabetes Patients: Effect of Metabolic Control.

Journal of clinical medicine·2025

Same author

Risk factors associated with low bone mineral density and childhood osteoporosis in a population undergoing skeletal growth: a cross-sectional analytic study.

Frontiers in endocrinology·2025

Search research articles

Related Experiment Video

Updated: Jul 2, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Levodopa and executive performance in Parkinson's disease: a randomized study.

Berta Pascual-Sedano¹, Jaime Kulisevsky, Manel Barbanoj

¹Department of Neurology (Movement Disorders Unit) and CIBERNED, Hospital de la Santa Creu i Sant Pau, Autonomous University of Barcelona, Spain.

Journal of the International Neuropsychological Society : JINS

|September 4, 2008

Summary

For Parkinson's disease (PD) patients, a slower release of levodopa (LD) may improve executive functions, particularly working memory, compared to faster-releasing forms. This suggests formulation impacts cognitive performance.

More Related Videos

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Related Experiment Videos

Last Updated: Jul 2, 2026

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Rating L-DOPA-Induced Dyskinesias in the Unilaterally 6-OHDA-Lesioned Rat Model of Parkinson's Disease

Published on: October 4, 2021

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Induction and Assessment of Levodopa-induced Dyskinesias in a Rat Model of Parkinson's Disease

Published on: October 14, 2021

Area of Science:

Neuroscience
Pharmacology
Cognitive Psychology

Background:

Parkinson's disease (PD) is associated with executive function deficits, often linked to frontal-basal ganglia circuit dysfunction.
Oral levodopa (LD) is a primary treatment for PD motor symptoms, but its impact on cognitive fluctuations, especially executive performance, is not fully understood.
The pharmacokinetic profile of LD, specifically the rate of plasma concentration increase, may influence cognitive outcomes.

Purpose of the Study:

To investigate the relationship between the pharmacokinetic profile of oral levodopa (LD) and acute changes in executive performance in Parkinson's disease (PD) patients.
To compare the effects of immediate-release (IR) versus controlled-release (CR) LD formulations on distinct executive functions.

Main Methods:

A randomized, double-blind, crossover study involving 14 PD patients.
Patients received both IR and CR LD doses.
Motor status, LD plasma levels, and performance on four executive function tasks (Wisconsin Card Sorting Test, Sternberg test, Stroop, Tower of Hanoi) were assessed before and for 6 hours after dosing.

Main Results:

Significant divergent effects were observed on the Sternberg test: improvement with CR-LD and worsening with IR-LD (specifically for the 6-digit task).
A marginal improvement was noted with CR-LD on the Wisconsin Card Sorting Test (WCST).
No significant differences were found for the Stroop or Tower of Hanoi tests between the two formulations.

Conclusions:

Acute executive-related performance in PD patients after LD administration can be influenced by the LD time-to-peak plasma concentration and task-specific demands.
A slower rise in LD plasma levels (CR formulation) appears to have a more beneficial effect on more demanding working memory tasks.
Further replication studies are needed to confirm these findings and their generalizability.